Metastatic Breast Cancer

Elizabeth A. Comen, MD, has been appointed associate professor in the department of medicine at NYU Langone Health’s Perlmutter Cancer Center.

Editor’s note: This is the third in a series of five stories from ASCO Voices, a session during ASCO Annual Meeting that focused on the human side of oncology.

CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.

Paolo Tarantino, MD, discusses the role of collaborative management of patients with metastatic breast cancer.

Paolo Tarantino, MD, speaks with Healio about future research directions in metastatic breast cancer.

Paolo Tarantino, MD, highlights modifiable risk factors for metastatic breast cancer.

Healio spoke with Paolo Tarantino, MD, about treatments in the pipeline for metastatic breast cancer.

Healio spoke with Paolo Tarantino, MD, about FDA approvals in metastatic breast cancer.

Compared with standard-of-care chemotherapy, trastuzumab deruxtecan demonstrated a statistically significant improvement in PFS among certain patients with metastatic breast cancer, according to a press release from the manufacturer.